Clinical Trial Update: Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC [Phase 1, Phase 2]

View source ↗

Summary

An early-stage trial is evaluating trametinib plus anlotinib with tislelizumab for KRAS-mutant non-small cell lung cancer; the Phase 1/2 study is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)
• Trametinib (trametinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: KRAS Mutation-Related Tumors, Advanced Lung Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING